An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes

Journal of Controlled Release

Volumn 96, Issue 3, 2004, Pages 449-461

  Abraham, Sheela A ^a,b   Edwards, Katarina ^c   Karlsson, Göran ^c   Hudon, Norma ^a   Mayer, Lawrence D ^a,b,d   Bally, Marcel B ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UPPSALA UNIVERSITY   (Sweden)

^d Celator Technologies Inc   (Canada)

Author keywords

(NH4)2SO4; 3H CHE; 3H cholesteryl hexadecyl ether; ammonium sulfate solution; Chol; cholesterol; Cryo transmission electron microscopy; cTEM; Liposomes; pH gradient; Remote loading; Topotecan

Indexed keywords

DRUG PRODUCTS; ENCAPSULATION; GLYCEROL; MANGANESE COMPOUNDS; PH EFFECTS; SULFUR COMPOUNDS;

CHOLESTROL; DRUG LOAD EFFICIENCY; DRUG RELEASE; LIPOSOMES;

BIOMEDICAL ENGINEERING;

CALCIMYCIN; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DIVALENT CATION; DRUG CARRIER; LIPID; LIPOSOME; MANGANESE CHLORIDE; MANGANESE DERIVATIVE; MANGANESE SULFATE; PROTON; SODIUM SULFATE; TOPOTECAN;

ARTICLE; CRYOELECTRON MICROSCOPY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; EVALUATION; IN VITRO STUDY; MEMBRANE; PH; PRIORITY JOURNAL;

AMMONIUM SULFATE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CALCIMYCIN; CHEMISTRY, PHARMACEUTICAL; CITRATES; CRYOELECTRON MICROSCOPY; DRUG COMPOUNDING; HYDROGEN-ION CONCENTRATION; LIPIDS; LIPOSOMES; MANGANESE; MEMBRANES, ARTIFICIAL; PARTICLE SIZE; SOLVENTS; SULFATES; TOPOTECAN;

EID: 2142649179     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.02.017     Document Type: Article

References (53)

1. Wall M.E. Camptothecin and taxol: discovery to clinic. Med. Res. Rev. 18:1998;299-314
2. Ulukan H., Swaan P.W. Camptothecins: a review of their chemotherapeutic potential. Drugs. 62:2002;2039-2057
3. Pizzolato J.F., Saltz L.B. The camptothecins. The Lancet. 361:2003;2235-2242
4. Broom C. Clinical studies of topotecan. Ann. N. Y. Acad. Sci. 803:1996;264-271
5. Herzog T.J. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist. 7(Suppl. 5):2002;3-10
6. Dunton C.J. New options for the treatment of advanced ovarian cancer. Semin. Oncol. 24:1997;S5-2-S5-11
7. Emerson D.L. Liposomal delivery of camptothecins. PSTT. 3:2000;205-209
8. Takimoto C.H., Wright J., Arbuck S.G. Clinical applications of the camptothecins. Biochim. Biophys. Acta. 1400:1998;107-119
9. Grochow L.B., Rowinsky E.K., Johnson R., et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. 20:1992;706-713
10. Wall M.E., Wani M.C., Nicholas A.W., et al. Plant antitumor agents: 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem. 36:1993;2689-2700
11. Fassberg J., Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81:1992;676-684
12. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:1985;14873-14878
13. Hertzberg R.P., Caranfa M.J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 11:1989;4629-4638
14. Burke T.G. Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. Ann. N. Y. Acad. Sci. 803:1996;29-31
15. Burke T.G., Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. 37:1994;40-46
16. Emerson D.L., Besterman J.M., Brown H.R., et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res. 55:1995;603-609
17. Larsen A.K., Gilbert C., Chyzak G., et al. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin toward human colon carcinoma cells. Cancer Res. 61:2001;2961-2967
18. Kehrer D.K.S., Bos A.M., Verweij J., et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J. Clin. Oncol. 20:2002;1222-1231
19. Hatefi A., Amsden B. Camptothecin delivery methods. Pharm. Res. 19:2002;1389-1399
20. Burke T.G., Bom D. Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann. N. Y. Acad. Sci. 922:2000;36-45
21. Sadzuka Y., Hirotsu S., Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett. 127:1998;99-106
22. Kehrer D.F., Bos A.M., Verweij J., et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J. Clin. Oncol. 20:2002;1222-1231
23. Lynam E., Landfair D.J., Wiles M.E. Camptothecin analogue efficacy in vitro: effect of liposomal encapsulation of GI147211C (NX211). Drug Deliv. 6:1999;51-62
24. Desjardins J.P., Abbott E.A., Emerson D.L., et al. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs. 12:2001;235-245
25. Tardi P., Choice E., Masin D., et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 60:2000;3389-3393
26. Burke T.G., Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J. Pharm. Sci. 83:1994;967-969
27. Burke T.G., Mishra A.K., Wani M.C., Wall M.E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry. 32:1993;5352-5364
28. Subramanian D., Muller M.T. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol. Res. 7:1995;461-469
29. Liu J.J., Hong R.L., Cheng W.F., et al. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs. 13:2002;709-717
30. Lasic D.D., Frederik P.M., Stuart M.C., et al. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 312:1992;255-258
31. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta. 1151:1993;201-215
32. Bolotin E.M., Cohen R., Bar L.K., et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes. J. Liposome Res. 4:1994;455-479
33. Deamer D.W., Nichols J.W. Proton flux mechanisms in model and biological membranes. J. Membr. Biol. 107:1989;91-103
34. Fenske D.B., Wong K.F., Maurer E., et al. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim. Biophys. Acta. 1414:1998;188-204
35. Cheung B.C., Sun T.H., Leenhouts J.M., Cullis P.R. Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim. Biophys. Acta. 1414:1998;205-216
36. Abraham S.A., Edwards K., Karlsson G., et al. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim. Biophys. Acta. 1565:2002;41-54
37. Redelmeier T.E., Mayer L.D., Wong K.F., et al. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys. J. 56:1989;385-393
38. Harrigan P.R., Hope M.J., Redelmeier T.E., Cullis P.R. Determination of transmembrane pH gradients and membrane potentials in liposomes. Biophys. J. 63:1992;1336-1345
39. Blok M.C., van der Neut-Kok E.C., van Deenen L.L., de Gier J. The effect of chain length and lipid phase transitions on the selective permeability properties of liposomes. Biochim. Biophys. Acta. 406:1975;187-196
40. Mayer L.D., Tai L.C., Bally M.B., et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta. 1025:1990;143-151
41. Lasic D.D., Ceh B., Stuart M.C., et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta. 1239:1995;145-156
42. Liu X., Lynn B.C., Zhang J., et al. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J. Am. Chem. Soc. 124:2002;7650-7651
43. Mayer L.D., Madden T.D., Bally M.B., Cullis P.R. pH gradient-mediated drug entrapment in liposomes. Liposome Technology. 2. Gregoriadis G '(Gregoriadis G)'Gregoriadis Gs)'. 1984;27-44 CRC Press, Boca Raton
44. Cullis P.R., Hope M.J., Bally M.B., et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta. 1331:1997;187-211
45. Maurer-Spurej E., Wong K.F., Maurer N., et al. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim. Biophys. Acta. 1416:1999;1-10
46. Gabizon A., Goren D., Cohen R., Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release. 53:1998;275-279
47. Li X., Hirsh D.J., Cabral-Lilly D., et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim. Biophys. Acta. 1415:1998;23-40
48. Streltsov S.A., Grokhovsky S.L., Kudelina I.A., et al. The behavior of the DNA topoisomerase I inhibitor topotecan in aqueous solution. J. Biomol. Struct. Dyn. 18:2001;913-914
49. Tong W.Q., Clarke J., Franklin M.L., et al. Identification and characterization of the sulfate precipitate in GI147211C IV formulation. PDA J. Pharm. Sci. Technol. 50:1996;326-329
50. Haleblian J.K. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci. 64:1975;1269-1288
51. Byrn S.R., Pfeiffer R.R., Stowell J.G. Introduction to the solid-state chemistry of drugs. Solid-State Chemistry of Drugs. 2nd ed. 1999;SSCI-Inc. West-Lafayette, IN. ISBN: 0-9670-6710-3
52. Boman N.L., Mayer L.D., Cullis P.R. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta. 1152(2):1993;253-258
53. Webb M.S., Harasym T.O., Masin D., et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models. Br. J. Cancer. 72(4):1995;896-904